CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Immunotherapeutic GSK2132231Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00896480
NCT00896480Phase 2Completed
CompareCT.gov

Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

GlaxoSmithKline·interventional·Posted May 11, 2009·Updated Apr 8, 2021

In Brief

A Phase 2 clinical trial evaluating Immunotherapeutic GSK2132231A for Melanoma. Completed, enrolled 24 participants across 8 sites in 2 countries.

Detailed Summary

The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and progressive metastatic cutaneous melanoma. The safety of the treatment will also be assessed just as its immunogenicity in terms of the humoral and cellular immune response induced by the GSK2132231A immunotherapeutic. Translational research objectives are to assess the effects of the study treatment in terms of various biological variables.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesBelgium, France
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 11, 2009
Enrollment StartMay 19, 2009
Primary CompletionNov 3, 2014
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.1 years ago

Interventions

Immunotherapeutic GSK2132231Abiological

Administration by intramuscular injection